Streetbeat News

Products Services

SCLX

Scilex Bio, a joint venture by Scilex Holding Company, is advancing a Phase 2 trial for KDS2010, a novel oral tablet for Alzheimer's Disease. The trial will include a U.S. patient cohort in 2025.

Portfolio Pulse from

December 11, 2024 | 6:00 pm

LMT

Lockheed Martin is experiencing a price pullback, presenting a buying opportunity due to its strong investment case, steady revenue growth, and a record $165 billion backlog. The company continues to secure high-profile contracts and advances in AI and drone technologies, while maintaining shareholder-friendly practices such as a 2.6% yield, 22 years of dividend growth, and share buybacks.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

MRCY

Mercury Systems, Inc. has launched new digital signal processing products using Altera's Agilex 9 FPGAs, enhancing their mission-critical processing capabilities.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

NTIP

Network-1 Technologies, Inc. has expanded its M2M/IoT patent portfolio to 55 patents worldwide with the issuance of a new U.S. patent.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

BIOA

Levi & Korsinsky has initiated an investigation into BioAge Labs, Inc. (NASDAQ:BIOA) for potential securities fraud following the discontinuation of its STRIDES Phase 2 trial due to safety concerns.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

PLTR

Palantir Technologies (NASDAQ:PLTR) is expected to see a significant increase in its stock price on December 13, potentially due to upcoming events or announcements related to its artificial intelligence operations.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

CBOE

CME

ICE

MKTX

NDAQ

The Securities and Exchanges industry is expected to benefit from product innovation, increased market volatility, and strategic economic models. Stocks like ICE, CME, NDAQ, CBOE, and MKTX are highlighted, though regulatory compliance remains a challenge.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

TSLA

Tesla is considered a 'Strong Buy' due to its strong fundamentals and multiple positive catalysts, including the upcoming budget Model Q, diversified ventures in energy and AI, and promising products like the Cybertruck.

Portfolio Pulse from

December 11, 2024 | 5:45 pm

ERIC

Ericsson's private 5G network has been chosen by Epiroc to enhance digital transformation in mining operations in Mexico. This partnership could positively impact Ericsson's stock.

Portfolio Pulse from

December 11, 2024 | 5:30 pm

CADL

Candel Therapeutics' phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Despite financial challenges, this success supports a potential FDA submission by mid-2025.

Portfolio Pulse from

December 11, 2024 | 5:30 pm